UNSTRUCTURED
Based on the Tofts-Kety model, the clinical application value of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) monitoring in the data measurement of ovarian cancer is explored, in order to provide more comprehensive measurement information for clinical measurement. In this study, the Tofts-Kety pharmacokinetic model was first established to measure the quantitative parameter volume transfer constant (Ktrans), the inter-plasma rate constant (Kep), and the volume fraction of extravascular extracellular space in unit volume tissue (Ve). 52 patients with routine pelvic floor examination and dynamic contrast-enhanced magnetic resonance imaging (Siemens Magnetom Verio 3.0T superconducting MR) from January 2015 to March 2019 were collected as research subject. The relationship between the parameters of DCE-MRI and the benign and malignant ovarian tumors was analyzed. The operating characteristic curve (ROC) analysis was used to obtain the optimal parameter values and optimal diagnostic thresholds for identifying the benign and malignant ovarian tumors, and the corresponding sensitivity, specificity, positive predictive value and negative predictive value. The results showed that different types of time-signal curve (TIC) had significant statistical significance in the differential measurement of benign and malignant ovarian tumors (P<0.05). The Ktrans, Kep and Ve values of the solid parts of benign and malignant ovarian tumors were statistically significant (P<0.05), it can be known that the measurement limit of the electrode for ovarian cancer SK0V-3 cells is 2.9cell ml-1. The relative standard deviation of the immunosensor is 11.12% after repeated measurement in PBS solution of 0.1mol-1. In summary, DCE-MRI, as a non-invasive imaging technique that can measure information on tumor microcirculation function, has important significance for the differential measurement of benign and malignant tumors.